<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02090738</url>
  </required_header>
  <id_info>
    <org_study_id>4-2013-0941</org_study_id>
    <nct_id>NCT02090738</nct_id>
  </id_info>
  <brief_title>A Randomized, Open-label Study on Helicobacter Pylori Eradication With Standard Triple Regimen Plus Acetazolamide</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Helicobacter pylori infection is associated with several gastric diseases, including&#xD;
      gastritis, peptic and duodenal ulcers, gastric carcinoma and MALToma. In 1994, the WHO&#xD;
      classified the organism as a type 1 carcinogen. In order to eradicate H. pylori, at least two&#xD;
      antibiotics and a proton pump inhibitor are used as a standard therapy regimen. Emerging&#xD;
      antibiotic resistance to metronidazole or clarithromycin, however, has made successful&#xD;
      treatment of infection progressively more difficult, with the success rate of standard triple&#xD;
      therapy now at 70%, well below the 80% required for treatment of infectious diseases.&#xD;
      Therefore, new treatment regimen is required for successful H. pylori eradication.&#xD;
&#xD;
      On the other hands, many in vitro studies revealed that bacterial carbonic anhydrase in H.&#xD;
      pylori has an important role for surviving of H. pylori in the stomach. It was demonstrated&#xD;
      that mutation of carbonic anhydrase affected survival of H. pylori. The investigators&#xD;
      therefore expected that administration of carbonic anhydrase inhibitor (acetazolamide) with&#xD;
      standard H. pylori eradication regimen would increase the eradication rate. Here, the&#xD;
      investigators aim to evaluate the efficacy of standard triple regimen plus acetazolamide for&#xD;
      H. pylori eradication.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>H. pylori eradication rate</measure>
    <time_frame>1 month from the eradication therapy</time_frame>
    <description>H. pylori eradication rate will be assessed by urea breath test after eradication therapy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>H. Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide group</intervention_name>
    <arm_group_label>Arm1</arm_group_label>
    <other_name>Esomeprazole (Nexium®, AstraZeneca Korea, Co. Ltd., Seoul, Korea) 40 mg, bid, for 7 days</other_name>
    <other_name>Amoxicillin (Kymoxin®, Yuhan Co. Ltd., Seoul, Korea) 1 g, bid, for 7 days</other_name>
    <other_name>Clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg, bid, for 7 days</other_name>
    <other_name>Acetazolamide (Diamox®, SK Chemicals Co. Ltd., Suwon, Korea) 250mg, bid, for 7 days</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard regimen group</intervention_name>
    <arm_group_label>Arm2</arm_group_label>
    <other_name>Esomeprazole (Nexium®, AstraZeneca Korea, Co. Ltd., Seoul, Korea) 40 mg, bid, for 7 days</other_name>
    <other_name>Amoxicillin (Kymoxin®, Yuhan Co. Ltd., Seoul, Korea) 1 g, bid, for 7 days</other_name>
    <other_name>Clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg, bid, for 7 days</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age, between 19 and 70&#xD;
&#xD;
          2. H. pylori infected patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous history of H. pylori eradication&#xD;
&#xD;
          2. Previous history of gastrectomy&#xD;
&#xD;
          3. Administration of PPI, H2 blocker, antibiotics, or bismuth within 1 month prior to&#xD;
             enrollment&#xD;
&#xD;
          4. Allergy to sulfonamide&#xD;
&#xD;
          5. Electrolyte imbalance&#xD;
&#xD;
          6. Adrenal insufficiency&#xD;
&#xD;
          7. Pregnancy or breast milk feeding&#xD;
&#xD;
          8. Active infection&#xD;
&#xD;
          9. Severe hepatic dysfunction&#xD;
&#xD;
         10. Severe renal dysfunction&#xD;
&#xD;
         11. Severe bone marrow dysfunction&#xD;
&#xD;
         12. Significant neurologic or psychologic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>severnace Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seodaemun-gu</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>March 14, 2014</study_first_submitted>
  <study_first_submitted_qc>March 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2014</study_first_posted>
  <last_update_submitted>April 27, 2014</last_update_submitted>
  <last_update_submitted_qc>April 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Acetazolamide</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

